Endogenex announced today that it completed enrollment in the ReCET clinical study of its endoscopic diabetes treatment. ReCET enrolled 350 patients across approximately 40 clinical sites in the U.S. and Australia. It evaluates the safety and effectiveness of the Endogenex System in adult patients with T2D whose blood glucose levels are … [Read more...] about Endogenex completes enrollment in trial of endoscopic diabetes treatment
Endogenex
Endogenex closes $50M Series C extension to support endoscopic diabetes procedure
Endogenex announced today that it closed a $50 million extension of its Series C financing round. Arboretum Ventures joined as a new lead investor alongside existing investors participating in the round. It builds on the $88 million Series C closed in June 2024, bringing the total round to $138 million. Minneapolis-based Endogenex plans to … [Read more...] about Endogenex closes $50M Series C extension to support endoscopic diabetes procedure
Endogenex has positive data for pulsed electric field tech for diabetes
Endogenex today announced new findings supporting its technology for improving outcomes in individuals with type 2 diabetes. Minneapolis-based Endogenex develops the Endogenex ReCET technology, which uses electroporation therapy to achieve re-cellularization. It utilizes non-thermogenic pulsed electric fields (PEF) to regenerate duodenal mucosal … [Read more...] about Endogenex has positive data for pulsed electric field tech for diabetes
